Skip to main
PVLA
PVLA logo

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics Inc. is positioned favorably in the biopharmaceutical sector due to its focus on rare genetic skin diseases, which currently lack approved therapies, highlighting a significant unmet medical need. The clinical development of its lead product candidate, QTORIN rapamycin, using the patented QTORIN platform, suggests innovative approaches that may enhance treatment efficacy and inter-rater reliability in clinical trials. The potential upside related to the Company’s CVM indication is a notable aspect of its financial outlook, indicating opportunities for value generation as the clinical data progresses.

Bears say

Palvella Therapeutics faces significant challenges due to the potential inadequacy of its intellectual property to protect against generic competition and alternative topical mTOR inhibitors. Additionally, the company has limited cash reserves, necessitating further capital infusion to advance the development and commercialization of its lead product, QTORIN rapamycin, which is still in the clinical trial phase and has only generated limited data to date. Furthermore, the small sample size in clinical data (n=12) raises concerns about the project's viability, contributing to a cautious outlook on the company's future performance.

PVLA has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 11 analysts, PVLA has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.